Tech Center 1600 • Art Units: 1634
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18108903 | BIOENGINEERED VASCULAR NETWORK | Non-Final OA | The Regents of the University of Michigan |
| 17632322 | METHODS OF BULK DROPLET VITRIFICATION | Non-Final OA | The General Hospital Corporation |
| 17870029 | MOLECULES AND METHODS FOR INCREASED TRANSLATION | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | Non-Final OA | BIOVENTURES, LLC |
| 17601303 | METHOD FOR PRODUCING KNOCK-IN CELL | Non-Final OA | OSAKA UNIVERSITY |
| 17605639 | GENE KNOCK-OUTS TO IMPROVE T CELL FUNCTION | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 17637737 | COMPOSITIONS FOR MONOCYTE AND MACROPHAGE POLARIZATION AND METHODS OF USE | Final Rejection | ORBSEN THERAPEUTICS LIMITED |
| 18086719 | GENE THERAPY | Non-Final OA | The University of Manchester |
| 17601174 | NUCLEIC ACID-BINDING PROTEIN | Non-Final OA | JAPAN SCIENCE AND TECHNOLOGY AGENCY |
| 17862622 | COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS | Final Rejection | SPARK THERAPEUTICS, INC. |
| 17759124 | 3D CELL CULTURE GEL KIT AND 3D CELL CULTURE METHOD USING THE SAME | Non-Final OA | GECOLL BIOMEDICAL CO., LTD. |
| 17756814 | IMPROVED PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE | Non-Final OA | Cbio A/S |
| 17751651 | RECOMBINANT ONCOLYTIC VIRUS, SYNTHETIC DNA SEQUENCE, AND APPLICATION THEREOF | Final Rejection | Wuhan Boweid Biotechnology Co., Ltd. |
| 17755447 | VIRUSES WITH MODIFIED CAPSID PROTEINS | Non-Final OA | SpyBiotech Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy